Vicious Interrelation of Stress Induced Cortisol, Hyperinsulinemia, Inflammation and Vascular Diseases in the Metabolic Syndrome
Joon Hwang, Ph.D.
we analyze recent findings suggesting that stress-induced glucocorticoid action may play a role in the development of hyperinsulinemia, inflammation, and vascular disease, focusing on the consequences and mechanisms of excessive insulin production and action. By discussing the role of specific signaling components in insulin action and the findings of chronic hyperinsulinemia, we can identify more effective treatments or lifestyle interventions to prevent or treat obesity, diabetes, atherosclerosis, and cancer.
Therapeutic strategies that normalize or decrease plasma insulin concentrations may play an important role in the prevention of aging, cardiovascular disease, and cancer, and in the treatment of age-related functional decline, obesity, type 2 diabetes, cardiovascular disease, and cancer.
Strategies to manage hyperinsulinemia should include caloric restriction, increasing hepatic insulin clearance, and maximizing insulin sensitivity. This can slow age-related physiological decline and prevent age-related diseases. Drugs that decrease insulin hypersecretion, normalize pulse insulin secretion, or increase hepatic insulin clearance also have the potential to prevent or delay the progression of hyperinsulinemia-mediated diseases. Future research should focus on novel strategies to minimize hyperinsulinemia early through the development of preventive and therapeutic technologies for hyperinsulinemia mediated diseases.
Inflammation as a Vascular Diseases Risk Factor
Cardiovascular diseases represent the main cause of death worldwide. Inflammation is the trigger of the early phases of the atherosclerotic process and an increase of inflammatory cytokines is associated with a higher risk of developing cardiovascular diseases.
Blood vessels should be viewed as living structures composed of cells such as endothelium and smooth muscle, not just inert tubes, and the interaction between blood components including cells, proteins, and small molecules and the endothelium surrounding the normal arterial wall is deeply related to the pathogenesis of this disease [64]. Vascular structures consist of endothelial cells (EC), smooth muscle cells (SMC), peripheral cells, fibroblasts, and many other types of cells. The atherosclerosis, endothelial barrier damage, peripheral cell loss, capillary thinning, and angiogenesis disorders are common pathologies of systemic vascular disease. The blood vessels, along with the nerves and lymphatic vessels, are surrounded by connective tissue membranes to form vascular neural bundles.
Atherosclerotic cardiovascular disease (ASCVD) has evolved from a disease of passive cholesterol accumulation to one driven by chronic inflammation, which initiates a number of biochemical and histological events that lead to atherosclerotic plaque formation and triggering plaque rupture events. Early investigations revealed a significant inflammatory cell infiltrate in atherosclerotic plaques.
The medical guidelines on the primary prevention of cardiovascular disease [83] and Lipids/biomarkers associated with increased ASCVD risk as follows:
Persistently elevated primary hypertriglyceridemia (≥175 mg/dL, nonfasting)
Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)
Elevated lipoprotein(a): A relative indication for its measurement is family history of premature ASCVD. A lipoprotein(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor, especially at higher levels of lipoprotein(a)
Elevated apolipoprotein B (≥130 mg/dL): A relative indication for its measurement would be triglyceride ≥200 mg/dL. A level ≥130 mg/dL corresponds to an LDL-C >160 mg/dL and constitutes a risk-enhancing factor.
Ankle-brachial index (<0.9)
Anti-Inflammatory Targeting Therapy for Atherosclerosis
One of the important causes of atherosclerosis is dyslipidemia. Drugs and treatments have been developed to reduce lipid risk factors for atherosclerosis, but correlation studies and treatment development for causal treatment methods related to inflammation, hyperinsulinemia, and insulin resistance are also important unmet needs.
Inflammation in atherosclerosis involves cellular elements of both innate immunity (e.g., macrophages and monocytes) and adaptive immunity (e.g., B cells and T cells) and a variety of cytokine cascades. Inflammation is a very useful therapeutic target in humans, and strategies to control inflammation have been successfully used to combat many other diseases, so inflammation is considered a preferred target for the treatment of atherosclerosis as well. Although several studies using animal models have demonstrated the efficacy of anti-inflammatory therapies, clinical trials still lack data on the consistency of clinical outcomes and side effects, as well as safety, which limits the development of effective arterioprotective drugs. However, ongoing research on cytokine targeting is a very important issue for stable diagnosis and treatment in new drug development and clinical application.
GLP-1RAs Therapy:
Inhibition therapy of NF-κB:
Anticytokine therapy:
Upregulation of anti-inflammatory cytokines:
Conclusion and Future Works
In the future, the establishment and implementation of strategies to significantly improve and manage metabolic syndrome are the most important individual and social issues, and should include appropriate restrictions to increase homeostasis, increasing hepatic insulin clearance, and maximizing insulin sensitivity. Such strategies are expected to delay age-related physiological decline and prevent age-related diseases. In addition, drugs that reduce insulin (hyper)secretion, normalize pulse insulin secretion, or increase hepatic insulin clearance also have the potential to prevent or delay the progression of hyperinsulinemia-mediated diseases.
New drug development and drug development New strategies should be focused on minimizing hyperinsulinemia early through the development of prevention and treatment technologies for hyperinsulinemia-mediated diseases. Future research should focus on developing new strategies for prevention, diagnosis, and treatment technologies for patient-tailored precision medicine based on balanced mechanistic studies of the correlations between diseases associated with metabolic syndrome.